Document Type
Article
Publication Date
8-21-2019
Abstract
BACKGROUND: Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor available as a single tablet and a three-drug combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) to treat HIV-1 infection. These analyses assessed pharmacokinetic (PK) interactions with co-administration.
METHODS: Two trials were conducted. Study 1: two-period, fixed-sequence; 8 healthy participants; Period 1, DOR 100 mg followed by ≥7-day washout; Period 2, TDF 300 mg once daily for 18 days, co-administration of DOR 100 mg on day 14. Study 2: three-period, crossover, 15 healthy participants; Treatment A, DOR 100 mg; Treatment B, 3TC 300 mg + TDF 300 mg; Treatment C, DOR 100 mg + 3TC 300 mg + TDF 300 mg; ≥7-day washout between periods.
RESULTS: Study 1: geometric mean ratios (GMRs) (90% confidence interval [CI]) of DOR AUC0–∞ and C24h (DOR + TDF / DOR) were 0.95 (0.80, 1.12) and 0.94 (0.78, 1.12), respectively. Study 2: GMRs (90% CI) of DOR AUC0–∞ and C24h (DOR + 3TC + TDF / DOR) were 0.96 (0.87, 1.06) and 0.94 (0.83, 1.06), respectively. GMRs (90% CI) of 3TC and tenofovir AUC0–∞ (DOR + 3TC + TDF / 3TC + TDF) were 0.94 (0.88, 1.00) and 1.11 (0.97, 1.28), respectively. Study drugs were generally well tolerated.
CONCLUSIONS: Multiple doses of TDF did not have a clinically meaningful effect on DOR PK. The PK of DOR were similar when administered alone or in combination with 3TC and TDF. DOR had no meaningful effect on the PK of 3TC and tenofovir.
Recommended Citation
Anderson, Matt S.; Gilmartin, Jocelyn; Fan, Li; Yee, Ka Lai; Kraft, Walter K.; Triantafyllou, Ilias; Reitmann, Christina; Guo, Ying; Liu, Rachael; and Iwamoto, Marian, "No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration." (2019). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 110.
https://jdc.jefferson.edu/petfp/110
PubMed ID
31433304
Language
English
Comments
This is the author’s version of a work accepted for publication by International Medical Press. Changes resulting from the publishing process, including peer review, editing and formatting, might not be reflected in this document. A definitive version was published in Antiviral Therapy, August ©2019 International Medical Press.
The published version is available at https://doi.org/10.3851/IMP3324.